A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

Abstract Advances in the understanding of Alzheimer’s disease (AD) suggest that pathogenesis is not directly related to plaque burden, but rather to soluble toxic amyloid-beta oligomers (AßO). Therapeutic antibodies targeting Aß monomers and/or plaque have shown limited efficacy and dose-limiting ad...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ebrima Gibbs, Judith M. Silverman, Beibei Zhao, Xubiao Peng, Jing Wang, Cheryl L. Wellington, Ian R. Mackenzie, Steven S. Plotkin, Johanne M. Kaplan, Neil R. Cashman
Format: article
Langue:EN
Publié: Nature Portfolio 2019
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/7e17d617f44d4cba8b63f9167f89ea62
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!